OxThera

Focus: OxThera is a Swedish biotech focused on kidney disease treatment, specifically primary hyperoxaluria, with a specialized pipeline of bacterial-based and enzyme therapeutics.

Nephrology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About OxThera

AI assessmentNot Hiring

No open roles listed right now. Follow OxThera to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Oxazyme

Hyperoxaluria

Phase 1/2

Clinical Trials (1)

NCT01127087Oxazyme in Patients With Hyperoxaluria

Phase 1/2

Help build intelligence for OxThera

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline in rare kidney disease with 7 active clinical programs, including Phase 3 programs (Oxabact OC5) approaching potential regulatory milestones
Specialized niche market (nephrology/primary hyperoxaluria) with less competition than crowded therapeutic areas
Founded in 2005 with sustained R&D focus suggests a mature private biotech with clear scientific mission

Watch Out For

Currently zero open job postings signals either hiring freeze, very early stage, or potential financial constraint
Private company status with no disclosed funding, revenue, or financial data creates uncertainty around growth trajectory and runway

Generated by Claude from OxThera's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Oxabact OC5 capsules

Primary Hyperoxaluria

Phase 1/2

Clinical Trials (1)

NCT02012985Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria

Phase 1/2

Oxalobacter formigenes

Primary Hyperoxaluria

Phase 2

Clinical Trials (1)

NCT02000219Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis

Phase 2

Oxalobacter formigenes

Primary Hyperoxaluria

Phase 2/3

Clinical Trials (1)

NCT00638703Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients

Phase 2/3

Oxalobacter formigenes

Primary Hyperoxaluria

Phase 2/3

Clinical Trials (1)

NCT01037231Phase 2/3 Oxabact Study

Phase 2/3

Oxabact OC5 - Oxalobacter formigenes Strain HC-1

Hyperoxaluria, Primary

Phase 3

Clinical Trials (1)

NCT03938272An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria

Phase 3

Oxabact OC5 - Oxalobacter formigenes HC-1

Primary Hyperoxaluria

Phase 3

Clinical Trials (1)

NCT03116685A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria

Phase 3

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Founded: 2005

Portfolio: 7 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo